Immunosuppression and risk of cervical cancer

Expert Review of Anticancer Therapy

Volumn 13, Issue 1, 2013, Pages 29-42

  Dugué, Pierre Antoine ^a   Rebolj, Matejka ^a   Garred, Peter ^a   Lynge, Elsebeth ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

autoimmune diseases; cervical cancer; diet; end stage renal disease; HIV AIDS; immunosuppression; inflammatory bowel disease; organ transplantation; sexually transmitted infections; smoking; systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

CANCER RISK; CAUSAL ATTRIBUTION; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFECT; ENTERITIS; GRAFT REJECTION; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; NUTRITIONAL HEALTH; ORGAN TRANSPLANTATION; PAPILLOMAVIRUS INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UTERINE CERVIX CANCER;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; ORGAN TRANSPLANTATION; PRECANCEROUS CONDITIONS; RISK FACTORS; SMOKING; UTERINE CERVICAL NEOPLASMS;

EID: 84871561491     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.159     Document Type: Review

References (138)

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999).
2. Helmerhorst TJ, Meijer CJ. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int. J. Gynecol. Cancer 12(3), 235-236 (2002).
3. Vajdic CM, van Leeuwen MT. What types of cancers are associated with immune suppression in HIV? Lessons from solid organ-transplant recipients. Curr. Opin. HIV AIDS 4(1), 35-41 (2009).
4. Clifford G, Franceschi S. Immunity, infection, and cancer. Lancet 370(9581), 6-7 (2007).
5. Wright TC. The Cervix: Chapter 35A, Immunosuppression and the Cervix: Human Immunodeficiency Virus (HIV). Blackwell Publishing, Malden, MA, USA (2006).
6. Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J. Natl Cancer Inst. Monographs (31), 41-46 (2003).
7. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT; Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged 18 months and for HIV infection and AIDS among children aged 18 months to 13 years-United States, 2008. MMWR. Recomm. Rep. 57(RR-10) 1-12, 2008.
8. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. Recomm. Rep. 58(RR-4), 1-207; quiz CE1 (2009).
9. Saslow D, Solomon D, Lawson HW et al.; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 137(4), 516-542 (2012).
10. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 370(9581), 59-67 (2007).
11. Dal Maso L, Polesel J, Serraino D et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br. J. Cancer 100(5), 840-847 (2009).
12. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch. Intern. Med. 170(15), 1337-1345 (2010).
13. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirusassociated cancers among persons with AIDS. J. Natl Cancer Inst. 101(16), 1120-1130 (2009).
14. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl Cancer Inst. 99(12), 962-972 (2007).
15. Leitao MM Jr, White P, Cracchiolo B. Cervical cancer in patients infected with the human immunodeficiency virus. Cancer 112(12), 2683-2689 (2008).
16. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 10(12), 1152-1159 (2009).
17. Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 123(1), 187-194 (2008).
18. Adler DH. The impact of HAART on HPV-related cervical disease. Curr. HIV Res. 8(7), 493-497 (2010).
19. Bollerup AR, Donoghoe MC, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003-2005. Scand. J. Public Health 36(2), 183-189 (2008).
20. Fleishman JA, Yehia BR, Moore RD, Gebo KA, Agwu AL. Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002-2008). Med. Care 50(5), 419-427 (2012).
21. Gravitt PE, Kirk GD. Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease. J. Infect. Dis. 201(5), 650-652 (2010).
22. Ahdieh-Grant L, Li R, Levine AM et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J. Natl Cancer Inst. 96(14), 1070-1076 (2004).
23. Minkoff H, Zhong Y, Burk RD et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J. Infect. Dis. 201(5), 681-690 (2010).
24. Shiels MS, Pfeiffer RM, Hall HI et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 305(14), 1450-1459 (2011).
25. Oster AM, Sullivan PS, Blair JM. Prevalence of cervical cancer screening of HIV-infected women in the United States. J. Acquir. Immune Defic. Syndr. 51(4), 430-436 (2009).
26. Logan JL, Khambaty MQ, D'Souza KM, Menezes LJ. Cervical cancer screening among HIV-infected women in a health department setting. AIDS Patient Care STDS 24(8), 471-475 (2010).
27. Dal Maso L, Franceschi S, Lise M et al.; Screening of HIV-positive women in Emilia-Romagna (SHER) Study. Selfreported history of Pap-smear in HIV-positive women in Northern Italy: a crosssectional study. BMC Cancer 10, 310 (2010).
28. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ-transplantation. Int. J. Cancer 125(8), 1747-1754 (2009).
29. Olaitan A, Freeman-Wang T. The Cervix: Chapter 35B, Immunosuppression and the Cervix: Other Immunosuppressive Disorders. Blackwell Publishing, MA, USA. (2006).
30. American College of Obstetricians and Gynecologists. Practice Bulletin no. 109: cervical cytology screening. Obstet. Gynecol. 114(6), 1409-1420 (2009).
31. Porreco R, Penn I, Droegemueller W, Greer B, Makowski E. Gynecologic malignancies in immunosuppressed organ homograft recipients. Obstet. Gynecol. 45(4), 359-364 (1975).
32. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58(3), 611-616 (1986).
33. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int. J. Cancer 60(2), 183-189 (1995).
34. Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transpl. Int. 19(11), 908-914 (2006).
35. Hwang JK, Moon IS, Kim JI. Malignancies after kidney transplantation: a 40-year single-center experience in Korea. Transpl. Int. 24(7), 716-721 (2011).
36. Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am. J. Cardiol. 103(4), 562-566 (2009).
37. Baccarani U, Piselli P, Serraino D et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig. Liver Dis. 42(1), 55-60 (2010).
38. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 4(6), 905-913 (2004).
39. Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl. Int. 13(Suppl. 1), S394-S398 (2000).
40. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br. J. Dermatol. 154(3), 498-504 (2006).
41. Hoshida Y, Tsukuma H, Yasunaga Y et al. Cancer risk after renal transplantation in Japan. Int. J. Cancer 71(4), 517-520 (1997).
42. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ-transplant recipients. JAMA 306(17), 1891-1901 (2011).
43. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 296(23), 2823-2831 (2006).
44. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 80(2 Suppl), S254-S264 (2005).
45. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ-transplant recipients: a systematic review. Drugs 67(8), 1167-1198 (2007).
46. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23(2), 101-113 (2000).
47. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved-editorial. Am. J. Nephrol. 18(2), 89-95 (1998).
48. Kato S, Chmielewski M, Honda H et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3(5), 1526-1533 (2008).
49. Luesley D, Simon L. Colposcopy and Programme Management, Guidelines for the NHS Cervical Screening Programme, (2nd Edition). NHSCSP Publication No 20, Sheffield, UK (2010).
50. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin. J. Am. Soc. Nephrol. 2(3), 604-610 (2007).
51. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol. Dial. Transplant. 17(10), 1786-1789 (2002).
52. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354(9173), 93-99 (1999).
53. van Leeuwen MT, Webster AC, Mccredie MR et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 340, c570 (2010).
54. Hartveit F, Bertelsen B, Thunold S, Maehle BO, Skaarland E, Christensen J. Risk of cervical intraepithelial neoplasia in women with glomerulonephritis. BMJ 302(6773), 375-377 (1991).
55. Wong G, Webster AC, Chapman JR, Craig JC. Reported cancer screening practices of nephrologists: results from a national survey. Nephrol. Dial. Transplant. 24(7), 2136-2143 (2009).
56. Kontaki E, Boumpas DT. Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J. Autoimmun. 35(3), 206-211 (2010).
57. Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum. Pathol. 17(3), 254-263 (1986).
58. Mellemkjær L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 40(4), 761-768 (1997).
59. Tarr T, Gyorfy B, Szekanecz E et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann. NY Acad. Sci. 1108, 76-82 (2007).
60. Kang KY, Kim HO, Yoon HS et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin. Rheumatol. 29(4), 381-388 (2010).
61. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 10(6), 394-400 (2001).
62. Bernatsky S, Boivin JF, Joseph L et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52(5), 1481-1490 (2005).
63. Hemminki K, Liu X, Ji J, Forsti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol. Oncol. 127(1), 180-185 (2012).
64. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19(8), 887-894 (2008).
65. Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA. Cancer screening in patients with systemic lupus erythematosus. J. Rheumatol. 33(1), 45-49 (2006).
66. Tam LS, Chan PK, Ho SC et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res. (Hoboken). 63(2), 269-276 (2011).
67. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 9(7), 542-544 (2000).
68. Bernatsky S, Ramsey-Goldman R, Gordon C et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford). 43(11), 1386-1389 (2004).
69. Klumb EM, Araújo ML Jr, Jesus GR et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J. Clin. Rheumatol. 16(4), 153-157 (2010).
70. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 50(11), 3619-3625 (2004).
71. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102(9), 2058-2069 (2007).
72. Rahier JF, Ben-Horin S, Chowers Y et al.; European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns. Colitis 3(2), 47-91 (2009).
73. Bhatia J, Bratcher J, Korelitz B et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J. Gastroenterol. 12(38), 6167-6171 (2006).
74. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 103(3), 631-636 (2008).
75. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 136(2), 451-458 (2009).
76. Lees CW, Critchley J, Chee N et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm. Bowel Dis. 15(11), 1621-1629 (2009).
77. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4), 854-862 (2001).
78. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 28(5), 598-605 (2008).
79. Mellemkjær L, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH. Crohn's disease and cancer risk (Denmark). Cancer Causes Control 11(2), 145-150 (2000).
80. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 52(8), 2415-2424 (2005).
81. Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br. J. Dermatol. 163(4), 800-806 (2010).
82. Bernatsky S, Hudson M, Pope J et al.; Canadian Scleroderma Research Group. Reports of abnormal cervical cancer screening tests in systemic sclerosis. Rheumatology (Oxford). 48(2), 149-151 (2009).
83. Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 21(4), 365-372 (2012).
84. Esmaeili H, Ghahremanzadeh K. Association of Pap smear abnormalities with autoimmune disorders. Pak. J. Biol. Sci. 14(10), 600-604 (2011).
85. Mercado U. [Abnormal cervicovaginal cytology in women with rheumatoid arthritis]. Ginecol. Obstet. Mex. 78(2), 94-98 (2010).
86. Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford). 47(5), 698-701 (2008).
87. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH.Rheumatoid arthritis and cancer risk. Eur. J. Cancer 32A(10), 1753-1757 (1996).
88. Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 20(6), 1001-1010 (2009).
89. Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 63(2), 352-358 (2011).
90. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9(5), 377-384 (2009).
91. Sopori M. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2(5), 372-377 (2002).
92. Hansen BT, Kjaer SK, Munk C et al. Early smoking initiation, sexual behavior and reproductive health-a large populationbased study of Nordic women. Prev. Med. 51(1), 68-72 (2010).
93. Vaccarella S, Herrero R, Snijders PJ et al.; IARC HPV Prevalence Surveys (IHPS) Study Group. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int. J. Epidemiol. 37(3), 536-546 (2008).
94. Brinton LA, Schairer C, Haenszel W et al. Cigarette smoking and invasive cervical cancer. JAMA 255(23), 3265-3269 (1986).
95. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention Volume 10, Cervix Cancer Screening (2005).
96. Appleby P, Beral V, Berrington De GA et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int. J. Cancer 118(6), 1481-1495 (2006).
97. Plummer M, Herrero R, Franceschi S et al.; IARC Multi-centre Cervical Cancer Study Group. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14(9), 805-814 (2003).
98. Fujita M, Tase T, Kakugawa Y et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. Tohoku J. Exp. Med. 216(4), 297-307 (2008).
99. Louie KS, Castellsague X, de Sanjose S et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol. Biomarkers Prev. 20(7), 1379-1390 (2011).
100. Berrington De Gonzalez A, Sweetland S, Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br. J. Cancer 90(9), 1787-1791 (2004).
101. Koshiol J, Schroeder J, Jamieson DJ et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am. J. Epidemiol. 164(2), 176-183 (2006).
102. Castle PE, Wacholder S, Lorincz AT et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J. Natl Cancer Inst. 94(18), 1406-1414 (2002).
103. Matsumoto K, Oki A, Furuta R et al.; Japan HPV And Cervical Cancer (JHACC) Study Group. Tobacco smoking and regression of low-grade cervical abnormalities. Cancer Sci. 101(9), 2065-2073 (2010).
104. MacLaughlan SD, Lachance JA, Gjelsvik A. Correlation between smoking status and cervical cancer screening: a cross-sectional study. J. Low. Genit. Tract Dis. 15(2), 114-119 (2011).
105. Byrne MM, Davila EP, Zhao W et al. Cancer screening behaviors among smokers and non-smokers. Cancer Epidemiol. 34(5), 611-617 (2010).
106. Miller WC, Ko EM. Does chlamydial infection increase the risk of cervical dysplasia? Sex. Transm. Infect. 87(5), 366-367 (2011).
107. Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho JL. Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes Infect. 11(4), 435-442 (2009).
108. Castle PE, Hillier SL, Rabe LK et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol. Biomarkers Prev. 10(10), 1021-1027 (2001).
109. Rebolj M, van Ballegooijen M, van Kemenade F, Looman C, Boer R, Habbema JD. No increased risk for cervical cancer after a broader definition of a negative Pap smear. Int. J. Cancer 123(11), 2632-2635 (2008).
110. Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol. 6(1), 45-57 (2011).
111. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357(9255), 539-545 (2001).
112. Boccardo E, Lepique AP, Villa LL. The role of inflammation in HPV carcinogenesis. Carcinogenesis 31(11), 1905-1912 (2010).
113. Hawes SE, Kiviat NB. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J. Natl Cancer Inst. 94(21), 1592-1593 (2002).
114. Samoff E, Koumans EH, Markowitz LE et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am. J. Epidemiol. 162(7), 668-675 (2005).
115. Silins I, Ryd W, Strand A et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer 116(1), 110-115 (2005).
116. Dillner J, Lehtinen M, Björge T et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J. Natl Cancer Inst. 89(17), 1293-1299 (1997).
117. Anttila T, Saikku P, Koskela P et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285(1), 47-51 (2001).
118. Koskela P, Anttila T, Bjørge T et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int. J. Cancer 85(1), 35-39 (2000).
119. Arnheim Dahlström L, Andersson K, Luostarinen T et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol. Biomarkers Prev. 20(12), 2541-2550 (2011).
120. Naucler P, Chen HC, Persson K et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J. Gen. Virol. 88(Pt 3), 814-822 (2007).
121. Smith JS, Muñoz N, Herrero R et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J. Infect. Dis. 185(3), 324-331 (2002).
122. Quint KD, De Koning MN, Geraets DT, Quint WG, Pirog EC. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol.Oncol. 114(3), 390-394 (2009).
123. Madeleine MM, Anttila T, Schwartz SM et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int. J. Cancer 120(3), 650-655 (2007).
124. Smith JS, Herrero R, Bosetti C et al.; International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl Cancer Inst. 94(21), 1604-1613 (2002).
125. Lehtinen M, Koskela P, Jellum E et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am. J. Epidemiol. 156(8), 687-692 (2002).
126. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis. Markers 23(4), 213-227 (2007).
127. Al-Daraji WI, Smith JH. Infection and cervical neoplasia: facts and fiction. Int. J. Clin. Exp. Pathol. 2(1), 48-64 (2009).
128. Johansen C, Mellemkjaer L, Frisch M, Kjaer SK, Gridley G, Olsen JH. Risk for anogenital cancer and other cancer among women hospitalized with gonorrhea. Acta Obstet. Gynecol. Scand. 80(8), 757-761 (2001).
129. Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition 12(4), 274-277 (1996).
130. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity 35(1), 13-22 (2011).
131. Powers HJ. Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J. Nutr. 135(12 Suppl), S2960-S2966 (2005).
132. Martín-López R, Hernández-Barrera V, De Andres AL, Garrido PC, De Miguel AG, García RJ. Breast and cervical cancer screening in Spain and predictors of adherence. Eur. J. Cancer Prev. 19(3), 239-245 (2010).
133. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 7(1), 113-126 (1996).
134. García-Closas R, Castellsagué X, Bosch X, González CA. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int. J. Cancer 117(4), 629-637 (2005).
135. Myung SK, Ju W, Kim SC, Kim H; Korean Meta-analysis (KORMA) Study Group. Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a meta-analysis. BJOG 118(11), 1285-1291 (2011).
136. González CA, Travier N, Luján-Barroso L et al. Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int. J. Cancer 129(2), 449-459 (2011).
137. Riboli E, Hunt KJ, Slimani N et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 5(6B), 1113-1124 (2002).
138. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 156(12), 880-91, W312 (2012).